Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Esperion Therapeutics Inc ESPR

Healthcare
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.


NDAQ:ESPR - Post by User

Esperion Therapeutics Inc
Bullboard Posts
User Avatar Image
(6)
•••
Post by BearDownAZon Jan 08, 2019 10:46am
85 Views
Post# 29200087

ESPR Licensing Agreement with Daiichi Sankyo Europe (DSE)

ESPR Licensing Agreement with Daiichi Sankyo Europe (DSE)Great news!

Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe

Also, discussed in the webcast of this announcement:

NDA and MMA for Bempedoic Acid LDL-C lowering on track to be filed in Q1'19 and Q2'19, respectively

Top-Line Results for Phase 1 Bempedoic Acid sustained release Study 201 expected Q1 2019

Phase 3 CLEAR Outcomes CVOT expected to reach full enrollment Q3 2019

Top Line for Bempedoic Acid Phase 2 T2D LDL-C lowering Trial with ezetimibe/BA combo pill expected H2 2019

Phase 3 Bempedoic Acid trial in type 2 diabetics for glucose lowering indication expected to launch H2 2019

Bring it on 2019!

BearDownAZ


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities